Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 2
1997 2
1998 8
1999 18
2000 29
2001 27
2002 26
2003 29
2004 21
2005 20
2006 23
2007 31
2008 34
2009 43
2010 36
2011 34
2012 32
2013 51
2014 34
2015 22
2016 25
2017 34
2018 48
2019 20
2020 43
2021 27
Text availability
Article attribute
Article type
Publication date

Search Results

665 results
Results by year
Filters applied: . Clear all
Page 1
Montelukast-induced adverse drug reactions: a review of case reports in the literature.
Calapai G, Casciaro M, Miroddi M, Calapai F, Navarra M, Gangemi S. Calapai G, et al. Pharmacology. 2014;94(1-2):60-70. doi: 10.1159/000366164. Epub 2014 Sep 2. Pharmacology. 2014. PMID: 25196099 Free article. Review.
Several clinical trials emphasized that montelukast can be considered a safe drug. However, recent evidence reconsidered the benefit/risk ratio of the use of montelukast for both paediatric and adult patients. ...A better understanding of the mechanisms causing ADRs …
Several clinical trials emphasized that montelukast can be considered a safe drug. However, recent evidence reconsidered the benefit/ …
Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis.
Zhang HP, Jia CE, Lv Y, Gibson PG, Wang G. Zhang HP, et al. Allergy Asthma Proc. 2014 Jul-Aug;35(4):278-87. doi: 10.2500/aap.2014.35.3745. Allergy Asthma Proc. 2014. PMID: 24992547 Review.
In acute asthma, montelukast could statistically improve peak expiratory flow percent predicted (p = 0.008) and reduce systemic corticosteroid intake (p = 0.005). Montelukast had low risk in hoarseness and insomnia. Our meta-analysis suggests that montelukast
In acute asthma, montelukast could statistically improve peak expiratory flow percent predicted (p = 0.008) and reduce systemic corti …
Montelukast and Neuropsychiatric Events in Children with Asthma: A Nested Case-Control Study.
Glockler-Lauf SD, Finkelstein Y, Zhu J, Feldman LY, To T. Glockler-Lauf SD, et al. J Pediatr. 2019 Jun;209:176-182.e4. doi: 10.1016/j.jpeds.2019.02.009. Epub 2019 Mar 21. J Pediatr. 2019. PMID: 30905424
OBJECTIVE: To examine the association between montelukast prescription and neuropsychiatric events in children with asthma. ...Cases were matched to up to 4 controls on birth year, year of asthma diagnosis, and sex. The exposures were dispensed prescriptions for montelu
OBJECTIVE: To examine the association between montelukast prescription and neuropsychiatric events in children with asthma. ...Cases …
Adverse drug reactions of montelukast in children and adults.
Haarman MG, van Hunsel F, de Vries TW. Haarman MG, et al. Pharmacol Res Perspect. 2017 Oct;5(5):e00341. doi: 10.1002/prp2.341. Pharmacol Res Perspect. 2017. PMID: 28971612 Free PMC article.
This study aims to obtain more insight into the safety profile of montelukast and to provide prescribing physicians with an overview of relevant adverse drug reactions in both children and adults. We retrospectively studied all adverse drug reactions on mo
This study aims to obtain more insight into the safety profile of montelukast and to provide prescribing physicians with an overview …
Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase().
Aldea Perona A, García-Sáiz M, Sanz Álvarez E. Aldea Perona A, et al. Drug Saf. 2016 Jan;39(1):69-78. doi: 10.1007/s40264-015-0360-2. Drug Saf. 2016. PMID: 26620206
Unexpectedly, completed suicides were reported more frequently for children (IC: 3.15; IC025: 1.98) than for adolescents (IC: 3.11; IC025: 2.61) or the total population (IC 1.95; IC025: 1.73). CONCLUSIONS: Neuropsychiatric disorders as side effects of montelukast we …
Unexpectedly, completed suicides were reported more frequently for children (IC: 3.15; IC025: 1.98) than for adolescents (IC: 3.11; IC025: 2 …
Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial.
Mahatme MS, Dakhale GN, Tadke K, Hiware SK, Dudhgaonkar SD, Wankhede S. Mahatme MS, et al. Indian J Pharmacol. 2016 Nov-Dec;48(6):649-653. doi: 10.4103/0253-7613.194854. Indian J Pharmacol. 2016. PMID: 28066101 Free PMC article. Clinical Trial.

The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was less in montelukast-levocetirizine group than in montelukast-fexofenadine group. CONCLUSION: The decrease in TNSS was more in

The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was

Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice.
Benard B, Bastien V, Vinet B, Yang R, Krajinovic M, Ducharme FM. Benard B, et al. Eur Respir J. 2017 Aug 17;50(2):1700148. doi: 10.1183/13993003.00148-2017. Print 2017 Aug. Eur Respir J. 2017. PMID: 28818882 Free article.
Although montelukast is generally well tolerated, postmarketing studies have reported serious neuropsychiatric adverse drug reactions (ADRs) leading to a United States Food and Drug Administration black box warning. The objective of this study was to determine the i …
Although montelukast is generally well tolerated, postmarketing studies have reported serious neuropsychiatric adverse drug re …
The efficacy and safety of H1-antihistamine versus Montelukast for allergic rhinitis: A systematic review and meta-analysis.
Wei C. Wei C. Biomed Pharmacother. 2016 Oct;83:989-997. doi: 10.1016/j.biopha.2016.08.003. Epub 2016 Aug 11. Biomed Pharmacother. 2016. PMID: 27522261 Review.
METHODS: We searched the databases of Pubmed, the Cochrane Library, Nature and Science as well as Wanfang data and CNKI from 2000 to March 2016, using key words "Montelukast SAH" or "H1-antihistamine Montelukast", or "Loratadine Montelukast", or "Desloratadin …
METHODS: We searched the databases of Pubmed, the Cochrane Library, Nature and Science as well as Wanfang data and CNKI from 2000 to March 2 …
Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.
Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Chien JW, Jacobsohn DA, Pavletic SZ, Martin PJ, Storer BE, Inamoto Y, Chai X, Flowers MED, Lee SJ. Williams KM, et al. Biol Blood Marrow Transplant. 2016 Apr;22(4):710-716. doi: 10.1016/j.bbmt.2015.10.009. Epub 2015 Oct 22. Biol Blood Marrow Transplant. 2016. PMID: 26475726 Free PMC article. Clinical Trial.
We hypothesized that inhaled fluticasone, azithromycin, and montelukast (FAM) with a brief steroid pulse could avert progression of new-onset BOS. ...
We hypothesized that inhaled fluticasone, azithromycin, and montelukast (FAM) with a brief steroid pulse could avert progression of n …
Risk of Psychiatric Adverse Events Among Montelukast Users.
Sansing-Foster V, Haug N, Mosholder A, Cocoros NM, Bradley M, Ma Y, Pennap D, Dee EC, Toh S, Pestine E, Petrone AB, Kim I, Lyons JG, Eworuke E. Sansing-Foster V, et al. J Allergy Clin Immunol Pract. 2021 Jan;9(1):385-393.e12. doi: 10.1016/j.jaip.2020.07.052. Epub 2020 Aug 11. J Allergy Clin Immunol Pract. 2021. PMID: 32795564
BACKGROUND: There have been conflicting results from observational studies regarding the risk of psychiatric adverse events (PAEs) with montelukast use. OBJECTIVE: To determine whether there are associations of depressive disorders, self-harm, and suicide with use o …
BACKGROUND: There have been conflicting results from observational studies regarding the risk of psychiatric adverse events (PAEs) wi …
665 results